Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109804 | 0.90 | PPARG (0.57) | PPARGLMNASMN1; SMN2 | |
| SCHEMBL5107810 | 0.86 | PPARG (0.45) | PPARGL3MBTL1ACACBPDE4DLIPE | |
| SCHEMBL5113595 | 0.82 | PPARG (0.45) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5111431 | 0.81 | PPARG (0.49) | PPARGLIPELMNATSHRSMN1; SMN2 | |
| SCHEMBL5110500 | 0.80 | PPARG (0.45) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5112219 | 0.80 | PPARG (0.43) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5120234 | 0.79 | PPARG (0.51) | PPARGL3MBTL1ACACBLIPEBCHE | |
| SCHEMBL5114363 | 0.77 | PPARG (0.48) | PPARGL3MBTL1LIPELMNATSHR | |
| SCHEMBL6036320 | 0.75 | PPARG (0.54) | PPARGFABP4FABP5PDE4DCHRM1 | |
| SCHEMBL5120850 | 0.75 | PPARG (0.47) | PPARGL3MBTL1ACACBLIPEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885L3MBTL1 2694/4885ACACB 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.